RenovoRx (RNXT) CEO’s family trust buys shares and new warrants

Rhea-AI Filing Summary

RenovoRx, Inc. director and CEO Shaun Bagai reported indirect purchases through The Bagai Family Trust on March 20, 2026. The trust bought 24,300 shares of common stock and 12,150 warrants in a private placement for an aggregate of $25,000.

After these transactions, the trust holds 313,357 shares of common stock and 12,150 warrants, while Bagai also holds 50,983 shares directly. The warrants are exercisable immediately and can be converted into 12,150 shares of common stock at an exercise price of $1.9326 per share.

The warrants expire on the earlier of March 30, 2029 or 30 days after RenovoRx reports at least $1.5 million in product sales revenue for any calendar quarter in a quarterly or annual report.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bagai Shaun

(Last) (First) (Middle)

C/O RENOVORX, INC.

2570 W EL CAMINO REAL, SUITE 320

(Street)

MOUNTAIN VIEW CALIFORNIA 94040

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
RenovoRx, Inc. [ RNXT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/20/2026	03/20/2026	P		24,300	A	(1)	313,357(3)	I	The Bagai Family Trust
Common Stock								50,983(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrants	$1.9326	03/20/2026	03/20/2026	P		12,150		(2)	(2)	Common Stock	12,150	(1)	12,150	I	The Bagai Family Trust

Explanation of Responses:

1. The securities were purchased in a private placement on March 20, 2026 for an aggregate of $25,000.

2. The warrants are exercisable immediately upon issuance and expire on the earlier of (i) March 30, 2029 or (ii) 30 days following the date the Issuer reports at least $1.5 million in product sales revenue (excluding licensing fees, upfront milestones and grants, but including royalty revenue from product sales) for any calendar quarter in a quarterly or annual report.

3. 289,057 shares of common stock are held of record by The Bagai Family Trust and were previously reported as "directly" beneficially held by the Reporting Person.

	/s/ Shaun Bagai	03/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider buying did RenovoRx (RNXT) report for Shaun Bagai?

RenovoRx reported that The Bagai Family Trust, associated with CEO Shaun Bagai, purchased 24,300 common shares and 12,150 warrants on March 20, 2026. The private placement totaled $25,000, increasing the trust’s indirect ownership in the company’s equity and derivative securities.

How many RenovoRx (RNXT) shares does Shaun Bagai hold after this Form 4?

Following the reported transactions, The Bagai Family Trust holds 313,357 RenovoRx common shares, and Shaun Bagai directly holds 50,983 common shares. These figures reflect both indirect and direct ownership, giving investors a clearer picture of his total reported equity exposure.

What are the terms of the new RenovoRx (RNXT) warrants bought by the Bagai Family Trust?

The Bagai Family Trust acquired 12,150 RenovoRx warrants exercisable immediately at an exercise price of $1.9326 per share. They expire on March 30, 2029 or 30 days after RenovoRx reports at least $1.5 million in product sales revenue for any calendar quarter.

Was the RenovoRx (RNXT) insider purchase an open-market trade or private placement?

The filing specifies that the securities were purchased in a private placement on March 20, 2026 for an aggregate of $25,000. This indicates a negotiated transaction with the company rather than a standard open-market buy on a stock exchange.

How is The Bagai Family Trust involved in RenovoRx (RNXT) insider holdings?

The Bagai Family Trust holds RenovoRx securities indirectly attributed to CEO Shaun Bagai. After the reported private placement, the trust holds 313,357 common shares and 12,150 warrants, which were previously or newly reported as indirectly beneficially owned in the Form 4 filing.